Sarepta Therapeutics, Inc. $SRPT Shares Bought by Janney Montgomery Scott LLC

Key Points

• Janney Montgomery Scott LLC increased its holdings in Sarepta Therapeutics by 123.5% during the 2nd quarter, owning a total of 28,743 shares valued at approximately $492,000.
• Institutional investors control 86.68% of Sarepta Therapeutics' stock, with significant increases in holdings reported by firms like Wellington Management and EcoR1 Capital.
• Sarepta Therapeutics had a 68.4% increase in revenue year-over-year, reporting $611.09 million for the quarter, while also exceeding analysts' expected earnings per share by $1.13.

Janney Montgomery Scott LLC increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 123.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 28,743 shares of the biotechnology company's stock after buying an additional 15,882 shares during the quarter. Janney Montgomery Scott LLC's holdings in Sarepta Therapeutics were worth $492,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after buying an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Sarepta Therapeutics by 2.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock worth $127,512,000 after buying an additional 41,408 shares during the period. EcoR1 Capital LLC increased its holdings in Sarepta Therapeutics by 67.8% in the 1st quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after buying an additional 522,386 shares during the period. Assenagon Asset Management S.A. raised its position in Sarepta Therapeutics by 21.8% during the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after acquiring an additional 155,358 shares in the last quarter. Finally, Aberdeen Group plc raised its position in Sarepta Therapeutics by 42.1% during the first quarter. Aberdeen Group plc now owns 650,279 shares of the biotechnology company's stock valued at $41,676,000 after acquiring an additional 192,584 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on SRPT shares. UBS Group reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Needham & Company LLC reiterated an "underperform" rating on shares of Sarepta Therapeutics in a research report on Monday, July 28th. Royal Bank Of Canada lifted their price target on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a "sector perform" rating in a research report on Wednesday, October 8th. Leerink Partnrs cut Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 18th. Finally, Wall Street Zen upgraded Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Eight investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have issued a Sell rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Hold" and a consensus price target of $34.42.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $22.51 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The business's 50 day moving average price is $19.61 and its 200-day moving average price is $29.44. The firm has a market capitalization of $2.20 billion, a PE ratio of -25.87 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The business's revenue was up 68.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.07 earnings per share. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.